Jan 26 (Reuters) - AstraZeneca Chief Executive
Pascal Soriot said on Tuesday that the British drugmaker is
working with Oxford University on a vaccine that will target the
South African variant of COVID-19.
"Having said that, we're also working on a vaccine with
Oxford University that will target the variant," Soriot told
Italian daily La Repubblica in an interview https://bit.ly/2KWidAc
published late on Tuesday.
(Reporting by Kanishka Singh in Bengaluru; Editing by Leslie
Adler)